BIA
REGN icon

Bell Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bell Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Sell
32
-12
-27% -$8.17K ﹤0.01% 470
2026
Q1 		$34K Sell
44
-1
-2% -$766 0.01% 317
2025
Q4 		$34.7K Buy
45
+17
+61% +$11.5K 0.01% 308
2025
Q3 		$15.7K Hold
28
– – ﹤0.01% 485
2025
Q2 		$14.7K Sell
28
-15
-35% -$8.37K ﹤0.01% 526
2025
Q1 		$27.3K Buy
43
+12
+39% +$8.25K 0.01% 317
2024
Q4 		$22.1K Sell
31
-7
-18% -$5.88K ﹤0.01% 362
2024
Q3 		$39.9K Hold
38
– – 0.01% 257
2024
Q2 		$39.9K Buy
38
+1
+3% +$969 0.01% 251
2024
Q1 		$35.6K Buy
37
+2
+6% +$1.9K 0.01% 262
2023
Q4 		$30.7K Sell
35
-3
-8% -$2.47K 0.01% 263
2023
Q3 		$31.3K Buy
38
+1
+3% +$786 0.01% 236
2023
Q2 		$26.6K Sell
37
-2
-5% -$1.54K 0.01% 255
2023
Q1 		$32K Hold
39
– – 0.01% 221
2022
Q4 		$28.1K Buy
39
+3
+8% +$2.21K 0.01% 242
2022
Q3 		$25K Buy
36
+10
+38% +$6.29K 0.01% 227
2022
Q2 		$15K Buy
+26
New +$16.9K ﹤0.01% 331
2021
Q4 		$15K Sell
23
-1
-4% -$615 ﹤0.01% 375
2021
Q3 		$15K Buy
+24
New +$14.9K ﹤0.01% 357

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bell Investment Advisors's REGN Position: Q2 2026 in Review

Bell Investment Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 27% in Q2 2026, selling an estimated $8.17K and leaving 32 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Bell Investment Advisors first reported a position in REGN in Q3 2021 and has held it in 19 quarters since. The position peaked at $39.9K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bell Investment Advisors held 32 shares of Regeneron Pharmaceuticals worth $20K as of Q2 2026.
  • Bell Investment Advisors sold 12 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.17K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #470 holding.
  • Bell Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Bell Investment Advisors's Regeneron Pharmaceuticals position peaked at $39.9K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.